ADIL Earnings Adial Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–25 of 25
| Q2 2026 | 2026-06-30 | -11.25 | 2026-08-14 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.48 | 2026-05-08 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 3.20 | 2026-03-05 | 10-K |
| FY 2025 | 2025-12-31 | -11.93 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -2.00 | 2025-11-13 | 10-Q |
| Q2 2025 | 2025-06-30 | -4.61 | 2025-08-13 | 10-Q |
| Q1 2025 | 2025-03-31 | -8.52 | 2025-05-14 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 10.99 | 2025-03-04 | 10-K |
| FY 2024 | 2024-12-31 | -68.01 | 2025-03-04 | 10-K |
| Q3 2024 | 2024-09-30 | -9.50 | 2024-11-13 | 10-Q |
| Q2 2024 | 2024-06-30 | -14.75 | 2024-08-13 | 10-Q |
| Q1 2024 | 2024-03-31 | -54.75 | — | — |
| Q4 2023 (derived) | 2023-12-31 | -15.75 | 2024-04-01 | 10-K |
| FY 2023 | 2023-12-31 | -90.00 | 2024-04-01 | 10-K |
| Q3 2023 | 2023-09-30 | -29.50 | 2023-11-14 | 10-Q |
| Q2 2023 | 2023-06-30 | 24.00 | 2023-08-21 | 10-Q |
| Q1 2023 | 2023-03-31 | -68.75 | 2023-05-12 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -62.00 | 2023-03-30 | 10-K |
| FY 2022 | 2022-12-31 | -317.75 | 2023-03-30 | 10-K |
| Q3 2022 | 2022-09-30 | -75.50 | 2022-11-14 | 10-Q |
| Q2 2022 | 2022-06-30 | -99.00 | 2022-08-15 | 10-Q |
| Q1 2022 | 2022-03-31 | -81.25 | — | — |
| FY 2021 | 2021-12-31 | -650.00 | — | — |
| Q3 2021 | 2021-09-30 | -137.50 | — | — |
| Q2 2021 | 2021-06-30 | -156.25 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.